The financial impact of maintenance treatment in heroin addictive behavior: the case of Subutex (R)

Citation
P. Kopp et al., The financial impact of maintenance treatment in heroin addictive behavior: the case of Subutex (R), REV EPIDEM, 48(3), 2000, pp. 256-270
Citations number
15
Categorie Soggetti
Envirnomentale Medicine & Public Health
Journal title
REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE
ISSN journal
03987620 → ACNP
Volume
48
Issue
3
Year of publication
2000
Pages
256 - 270
Database
ISI
SICI code
0398-7620(200006)48:3<256:TFIOMT>2.0.ZU;2-L
Abstract
Background: The development of maintenance treatment for subjects with addi ctive behavior is an important public health issue. As such, the social eff ectiveness of maintenance products must be examined from an economical and social point of view. This paper aims at presenting the financial costs inv olved in the use of Subutex(R), a product commercialized since 1996. Methods: A complete typology of costs related to drug addiction and its con sequences was set up. Some of these costs were estimated on the basis of da ta drawn from the literature. The cost of Subutex(R) use fbr maintenance tr eatment was assessed and compared with the financial stakes including the p otential reduction of the economic and social cost of drug addiction. Results: Monthly treatment cost of Subutex(R) was 1252 FrF per drug abuser on maintenance treatment. By extrapolation, for a population of 40,000 drug abusers, the direct medical cost of Subutex(R) during a course of maintena nce treatment with general practitioner follow-up was estimated at 600 mill ions FrF. US data sources were applied to France to assess the cost of illn esses attributable to drug addiction. The cost reached 4.8 billions FrF. Th e cost of delinquency associated with drug addiction, which mostly concerns money laundered to purchase substances was an estimated 6.4 billions FrF. Finally, the cost of public anti-drug abuse programs was nearly 4.7 billion s FrF. Thus, the direct cost of drug addiction consequences reached 15.6 bi llions FrF. This cost should be compared with the annual cost of Subutex(R) for public organizations which was an estimated 600 millions FrF. Conclusions: The "profit" threshold of maintenance treatment with Subutex(R ) in terms of direct costs is very low. A decrease of only 4% of the costs associated with drug addiction would make it possible to balance the financ ial budget for the community. Our analysis does not take into acount absolu tely all the public health and safety aspects involved in the use of Subute x(R). It does however provide a useful assessment of the financial aspects of the question and justification for this therapeutic strategy from a budg etary point of view.